Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

VANCOUVER and SAN DIEGO, March 13 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three and nine months ended January 31, 2008 and an update on its programs.

Jim DeMesa, M.D., President & CEO of MIGENIX stated, "With the conclusion of our third fiscal quarter and now being halfway through our fourth quarter, we are looking forward to the completion of enrollment in the Phase III Omigard registration trial for preventing catheter-related infections being conducted by our partner, Cadence Pharmaceuticals. With completion of this trial, we expect to enter into a very important time of clinical results over the next half of the year (with both Omigard and celgosivir, our Phase II hepatitis C drug candidate) followed by our potential entry into the regulatory approval process in 2009 with Omigard."

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study being conducted by our development and commercialization partner Cadence Pharmaceuticals is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. Cadence expects they will complete enrollment of the 1,850 patients planned for the trial in the second quarter of 2008, with results available in the second half of 2008. If the results of the trial are positive, Cadence expects to submit a New Drug Application ("NDA") for omiganan 1% gel in the first half of 2009. Under the terms of the agreement with Cadence, MIGENIX will receive up to US$27 million in development and commercialization milestone payments, upon the achievement of specified milestones, starting with the US and European regulatory submission process; and a double-digit royalty on net sales. MIGENIX has been and continues to be in discussions with p
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Decision Resources Group finds ... directors in the United States ... market penetration will be the level of savings ... the expected lower cost to patients. Payers plan ... meet their pricing expectations in order to encourage ...
(Date:7/30/2014)...  Replikins Ltd. today released new data on changes ... the current outbreaks, the mean Ebola Reston gene Replikin ... 1995 and 2002 was 1.1; the mean Replikin Count ... in 2013, thus predicting the current outbreaks in humans. ... shown to be able to predict outbreaks (1).  For ...
(Date:7/30/2014)... Sales Horizons, a leader in sales training ... programs for companies engaged in complex B2B sales. , ... of salespeople over 25 years in market-leading Fortune 500 ... customized to address the unique sales challenges of companies ... program consists of two parts: Mastering the Complex ...
(Date:7/30/2014)... 30, 2014 July 30, 2014. ... biotechnology firm that provides DNA-based authentication and security solutions ... Vice President of Life Sciences, a newly created position, ... Dr. Hogan will lead APDN’s drive to build its ... biotech and healthcare customers, provide guidance to APDN’s R&D ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today ... the addition of two new members. Appointed to the company,s ... Chatfield. With their addition, the company board now has eight ... of the U. S. Selective Service System from November of ...
... Pa., Oct. 26 Cadient Group , ... today announced that it has been recognized as one of ... the Greater Philadelphia region for the second consecutive year. ... during the five year period from 2004-2008. Cadient Group ...
... , ... blue dye test alternative using innovative laser technology has been installed at ... processes. Bayer China has acquired Sepha ’s ‘BlisterScan’ machines for non-destructive leak testing ... ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Cadient Group Ranks as Deloitte Fast 50 Company for Greater Philadelphia Region for Second Consecutive Year 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 3
(Date:7/30/2014)... about what they eat, the Food and Drug Administration ... Nutrition Facts label found on nearly every food product ... Engineering News (C&EN), the weekly news magazine of ... and the fight that has ensued. , Britt Erickson, ... the Nutrition Facts label has remained largely the same ...
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... Calif. , July 30, 2014 ... with the United States Air Force Research Laboratory ... by Binghamton University to ... performance monitoring (HPM). The $425,000 project, with contributions ... packaging firm i3 Electronics, Inc. ( Endicott, ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... Nature Genetics, is based on data from more than ... but also discovered ten new genes. Altogether they explain ... The analysis produced some biologically insightful findings. Several ... let-7, which affects the regulation of other genes. This ...
... University of Leicester engineer has won a share of ... cancer. In an unusual move, Dr. Declan Bates, ... the University of Leicester, is co-recipient of 1,068,000 in ... the Engineering and Physical Sciences Research Council (EPSRC) and ...
... to determine if global warming threatens the polar bear population ... listing the polar bear as an endangered species, according to ... journal of the Institute for Operations Research and the Management ... ordered the Interior Department to decide by May 15 whether ...
Cached Biology News:How body size is regulated 2Engineer to spearhead research into cell metabolism and medical injuries 2Federal polar bear research critically flawed, says study in INFORMS journal 2
... controller is the successor to the original DS-U1. ... of the cameras in the Nikon DS camera ... interface. The DS-U2 transmits information at high speed, ... both hub and mass storage USB 2.0 interfaces. ...
...
... Liquid. 100 ml supplied as a ... remove antibodies from membrane-bound proteins without ... stripping chemiluminescent or radioisotopic signals from ... Western blots. Supplied as a 5X ...
... The 500 optimization kit is for ... of interest. The kit is recommended when ... biolistic system. The kit includes 0.25 g ... 1.6 micrometer diameter gold microcarriers, 100 each ...
Biology Products: